What's happened
The FDA has approved Eli Lilly's new pill, Foundayo, a GLP-1 receptor agonist for weight loss, offering a convenient alternative to injections. It is expected to be available from Monday, with prices ranging from $25 to $349 monthly, depending on insurance and dose. The drug shows promising weight loss results in clinical trials.
What's behind the headline?
The approval of Foundayo marks a significant shift in obesity treatment, emphasizing convenience and accessibility. As a small-molecule GLP-1 drug, it can be taken without restrictions, unlike peptide-based injectables. This will likely increase adoption among patients hesitant to use injections, potentially expanding the market. However, the modest weight loss compared to injectable options suggests it may serve as a complementary or alternative therapy rather than a replacement.
The clinical trial data indicates that higher doses can lead to an average weight loss of about 25 pounds over 16 months, with side effects primarily gastrointestinal, leading to discontinuation in some cases. The drug's inclusion in a government program to lower prices signals a strategic move to improve affordability, which could significantly impact public health by reducing obesity-related diseases.
The broader context involves ongoing debates about the long-term safety of GLP-1 drugs, especially concerning muscle mass loss and side effects. Experts emphasize the importance of combining medication with lifestyle interventions like resistance training to mitigate risks. The rapid approval process reflects a policy push to accelerate access, but it raises questions about long-term safety monitoring and equitable distribution across different populations.
Overall, Foundayo will likely become a key tool in obesity management, especially for those seeking a non-injectable option, but its success depends on careful prescribing, monitoring, and integration with lifestyle support.
What the papers say
The Independent reports that Eli Lilly's Foundayo will be available starting Monday, with prices for insured patients as low as $25 per month, and highlights its clinical trial results showing an average weight loss of 11.2% at the highest dose. AP News emphasizes the FDA's expedited review process, which reviewed the application in just 50 days, and notes the drug's comparable efficacy to existing oral GLP-1 options like Wegovy. The New York Times discusses the clinical trial outcomes, noting an average weight loss of around 12% over 72 weeks, and highlights the convenience of the oral formulation compared to injectable drugs. All sources agree on the significance of this development in expanding weight management options, with some cautioning about side effects and the importance of lifestyle interventions. The coverage underscores the broader trend of making weight-loss medications more accessible and affordable, with policy measures supporting lower prices and wider coverage.
How we got here
The approval follows the success of injectable GLP-1 drugs like Wegovy and Ozempic, which have been widely used for weight management and diabetes. The new pill, orforglipron, is part of a broader effort to improve access and affordability of weight-loss medications, with expedited FDA review processes and lower-cost options being introduced to address high drug prices and compliance issues.
Go deeper
More on these topics
-
The Food and Drug Administration is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
-
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares.
-
Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management.
-
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a